BURNABY, BC, Sept. 29 /CNW/ - Welichem Biotech Inc. (the "Company") (TSX-V: WBI), announced today that the Company filed its annual audited financials and MD & A. The net loss for the year ended May 31, 2009 was $2,701,954 (2008 - restated $2,503,756) and 16 cents per share (2008 - 34 cents per share). The loss per share and weighted average number of common shares outstanding were recalculated retroactively to reflect the ten-to-one share consolidation implemented on September 3, 2009.
Detailed information is available on SEDAR website (www.sedar.com).
About Welichem Biotech Inc.
Welichem Biotech Inc. is a publicly-traded biotechnology company developing therapeutic drugs in the fields of inflammatory diseases and cancer.
ON BEHALF OF THE BOARD
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. This press release contains forward-looking statements that include our belief as to the potential of our products. Certain risks and uncertainties such as our ability to successfully commercialize the products could cause the Company's actual results to differ materially from those in the forward-looking statements.
SOURCE Welichem Biotech Inc.
For further information: For further information: Genhui Chen, Tel.: (604) 432-1703, Email: email@example.com